<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Demographics and Baseline Characteristics of Patients</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2">Subject ID</th>
    <th rowspan="2">Part and Group
     <xref rid="tblfn1" ref-type="table-fn">a</xref>
    </th>
    <th rowspan="2">Sex and Age (Years)</th>
    <th rowspan="2">Weight (kg)</th>
    <th rowspan="2">MPS II-Related Intellectual Disability</th>
    <th rowspan="2">Genetic Analysis Results</th>
    <th colspan="2">Anti-IDS Antibody
     <hr/>
    </th>
   </tr>
   <tr>
    <th>Negative/Positive</th>
    <th>Antibody Titer</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>H1-01-01</td>
    <td>part 1, –</td>
    <td>male, 33</td>
    <td>47.5</td>
    <td>no</td>
    <td>c.1351_1355delCCGTA</td>
    <td>positive</td>
    <td>64</td>
   </tr>
   <tr>
    <td>H1-08-01</td>
    <td>part 1, –</td>
    <td>male, 63</td>
    <td>69.8</td>
    <td>no</td>
    <td>N63D</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-02-01</td>
    <td>part 2, L</td>
    <td>male, 6</td>
    <td>26.7</td>
    <td>yes</td>
    <td>recombination between IDS gene and IDS-2 gene</td>
    <td>positive</td>
    <td>4,096</td>
   </tr>
   <tr>
    <td>H1-02-03</td>
    <td>part 2, L</td>
    <td>male, 19</td>
    <td>69.9</td>
    <td>no</td>
    <td>–</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-03-01</td>
    <td>part 2, L</td>
    <td>male, 10</td>
    <td>52.0</td>
    <td>yes</td>
    <td>P.Q121R</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-03-02</td>
    <td>part 2, H</td>
    <td>male, 12</td>
    <td>43.2</td>
    <td>yes</td>
    <td>P.Q121R</td>
    <td>positive</td>
    <td>1</td>
   </tr>
   <tr>
    <td>H1-04-01</td>
    <td>part 2, H</td>
    <td>male, 14</td>
    <td>44.2</td>
    <td>yes</td>
    <td>–</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-05-01</td>
    <td>part 2, H</td>
    <td>male, 10</td>
    <td>29.7</td>
    <td>no</td>
    <td>–</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-05-02</td>
    <td>part 2, L</td>
    <td>male, 14</td>
    <td>61.4</td>
    <td>no</td>
    <td>–</td>
    <td>positive</td>
    <td>4</td>
   </tr>
   <tr>
    <td>H1-06-01</td>
    <td>part 2, L</td>
    <td>male, 7</td>
    <td>21.1</td>
    <td>no</td>
    <td>nonsense mutation of c.1327C &gt; T(p.R443x) in exon9</td>
    <td>positive</td>
    <td>4,096</td>
   </tr>
   <tr>
    <td>H1-06-02</td>
    <td>part 2, L</td>
    <td>male, 16</td>
    <td>37.8</td>
    <td>yes</td>
    <td>iduronate-2-sulfatase exon8(G365X 1092G &gt; T)</td>
    <td>negative</td>
    <td>–</td>
   </tr>
   <tr>
    <td>H1-07-01</td>
    <td>part 2, H</td>
    <td>male, 25</td>
    <td>44.7</td>
    <td>no</td>
    <td>IDS C.1326C &gt; T p.R443X</td>
    <td>positive</td>
    <td>512</td>
   </tr>
   <tr>
    <td>H1-08-02</td>
    <td>part 2, H</td>
    <td>male, 9</td>
    <td>31.4</td>
    <td>yes</td>
    <td>Ex8 TGG → TGA W337X</td>
    <td>positive</td>
    <td>8,192</td>
   </tr>
   <tr>
    <td>H1-08-03</td>
    <td>part 2, H</td>
    <td>male, 13</td>
    <td>42.8</td>
    <td>yes</td>
    <td>Ex9 CGG → CAG R468Q</td>
    <td>negative</td>
    <td>–</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Part 1 of the study was a dose-escalation study, and part 2 was a randomized study to evaluate the safety, pharmacokinetics, and exploratory efficacy of JR-141.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn1">
   <label>a</label>
   <p id="ntpara0010">L, 1.0 mg/kg/week; H, 2.0 mg/kg/week.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
